Amgen stock heads into the open after a sharp drop
Published on 09/17/2026 at 07:28 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
At the close on September 16, 2026, Amgen stock finished the session lower on the Nasdaq, losing around 5 percent as sector news weighed on the shares, with the move tied to fresh clinical data in the cardiovascular space. Compared with the Dow Jones Industrial Average, which fell 1.21% on the same date, Amgen underperformed the broader blue-chip benchmark.
September 16, 2026 in numbers
Amgen Inc. (ISIN US0311621009, Nasdaq: AMGN) saw its shares decline by about 5 percent on September 16, 2026, in a session marked by risk-off sentiment across United States equities following a rate hike signal from the Federal Reserve. According to Bolsamania, Amgen lost around 5 percent after the clinical failure of a Novartis cardiovascular medicine seen as a sector negative, amplifying the impact on the price-weighted Dow Jones index where the stock carries substantial weight. On the same day, the Dow Jones Industrial Average closed down 1.21%, while the broader S&P 500 index and the Nasdaq Composite also ended lower, underscoring that Amgen's drop exceeded the main benchmarks in percentage terms.
The selling in Amgen on September 16, 2026 came as investors reassessed exposure to cardiometabolic and cardiovascular drug pipelines following Novartis setbacks, with the Spanish market wrap by Bolsamania highlighting Amgen as a key drag on the Dow because of its relatively high index weighting. In the same environment, United States indices reacted to tighter monetary policy expectations, with coverage from Asia Daily noting that the Dow Jones fell 1.21% and the S&P 500 slipped 0.44% as higher rates and tightening signals pressured equities, adding a macro backdrop to Amgen's sector-specific decline.
Outlook today for Amgen stock
Looking ahead to today, September 17, 2026, investors in Amgen stock face a session framed by both company-specific pipeline attention and broader macro dynamics. Recent commentary on Amgen's resilience in past downturns and its dividend profile, as discussed by The Globe and Mail, may shape how income-focused investors interpret the recent volatility, especially given the stock's history of outperforming the S&P 500 in past stress episodes. In addition, Amgen is scheduled to participate in the Wells Fargo 21st Annual Healthcare Conference on September 10, 2026 per the company investor calendar at Amgen, an event that, while now in the rear-view mirror, has kept attention on management's messaging around growth drivers, pipeline assets and capital allocation, context that continues to inform today's trading narrative even as no new company-specific events are formally slated within the next few days.
